Constanze Ulmer-Eilfort
Director/Board Member chez EVOTEC SE
Profil
Constanze Ulmer-Eilfort is currently the Director at Proxygen Co., an Independent Member-Supervisory Board at Affimed NV, a Member-Supervisory Board at Evotec SE, and a Partner at Peters, Schönberger & Partner GbR.
Previously, he worked as a Partner at Baker Mckenzie LLP from 1998 to 2021.
Dr. Ulmer-Eilfort holds a graduate degree from the University of Pennsylvania, a doctorate degree from Freie Universität Berlin, and a graduate degree from Ludwig-Maximilians-Universität München.
Postes actifs de Constanze Ulmer-Eilfort
| Sociétés | Poste | Début |
|---|---|---|
| EVOTEC SE | Director/Board Member | 01/06/2021 |
| AFFIMED N.V. | Director/Board Member | 21/06/2023 |
Peters, Schönberger & Partner GbR
 Peters, Schönberger & Partner GbR Miscellaneous Commercial ServicesCommercial Services Peters, Schönberger & Partner is a Munich-based law firm that provides legal advice and data protection services. The German company specializes in auditing and creating annual financial statements, representing clients in state courts and arbitration, and providing practical and interdisciplinary support to foundations, non-profit organizations, and other charitable institutions. The firm also offers investment office services for large assets, as well as neutral assessment, arbitration, and consulting services for businesses. Peters, Schönberger & Partner is a competent partner for medium-sized and international companies, private equity firms, and NPOs. The company also provides advice and support on tax compliance management and GoBD. | Corporate Officer/Principal | 01/01/2022 |
Proxygen Co.
 Proxygen Co. Investment ManagersFinance Proxygen Co. is an American biotech company focused on the discovery and development of molecular glue degraders against targets of unmet medical need across various indications. Proxygen's headquarters and laboratory operations are based in an undisclosed location, and the private company employs talent both locally and remotely all over. The company maintains strategic partnerships with Merck & Co, Boehringer Ingelheim, and Merck KGaA to co-create synergies along the drug development pipeline. | Director/Board Member | 01/01/2022 |
Anciens postes connus de Constanze Ulmer-Eilfort
| Sociétés | Poste | Fin |
|---|---|---|
| Baker Mckenzie LLP | Corporate Officer/Principal | 01/01/2021 |
Formation de Constanze Ulmer-Eilfort
| University of Pennsylvania | Graduate Degree |
| Freie Universität Berlin | Doctorate Degree |
| Ludwig-Maximilians-Universität München | Graduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| AFFIMED N.V. | Health Technology |
| EVOTEC SE | Health Technology |
| Entreprise privées | 3 |
|---|---|
Peters, Schönberger & Partner GbR
Peters, Schönberger & Partner GbR Miscellaneous Commercial ServicesCommercial Services Peters, Schönberger & Partner is a Munich-based law firm that provides legal advice and data protection services. The German company specializes in auditing and creating annual financial statements, representing clients in state courts and arbitration, and providing practical and interdisciplinary support to foundations, non-profit organizations, and other charitable institutions. The firm also offers investment office services for large assets, as well as neutral assessment, arbitration, and consulting services for businesses. Peters, Schönberger & Partner is a competent partner for medium-sized and international companies, private equity firms, and NPOs. The company also provides advice and support on tax compliance management and GoBD. | Commercial Services |
Proxygen Co.
Proxygen Co. Investment ManagersFinance Proxygen Co. is an American biotech company focused on the discovery and development of molecular glue degraders against targets of unmet medical need across various indications. Proxygen's headquarters and laboratory operations are based in an undisclosed location, and the private company employs talent both locally and remotely all over. The company maintains strategic partnerships with Merck & Co, Boehringer Ingelheim, and Merck KGaA to co-create synergies along the drug development pipeline. | Finance |
| Baker Mckenzie LLP |
